NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza i...
Q3 2026
May 15, 2026
Q2 2026
Feb 17, 2026
Q1 2026
Nov 14, 2025
FY 2025
Sep 29, 2025
Q4 2025
